FEIBA provides rapid onset and sustained activity in the treatment of patients with haemophilia and inhibitors

Rapid onset -
sustained activity

FEIBA is formulated with multiple active components that quickly induce thrombin generation and maintain the coagulation process.1-3

  • Provides both factor II (prothrombin) and factor Xa for rapid and sustained thrombin generation1,2
  • Contains additional factors that target multiple sites within the coagulation system, to help sustain activity1

FEIBA provides:

  • Rapid onset (peak at 15 -30 minutes) of thrombin generation in an in vitro assay3
    - Plasma samples obtained from inhibitor patients without a current bleed
    - Clinical correlations between thrombin generation and the outcome of inhibitor bypassing activity with FEIBA have been demonstrated (n=3)4
  • 53.2% of bleeds stopped within 2 hours with 1 FEIBA infusion5
  • Sustained activity
    - Thrombin generation returns to baseline value 8 -12 hours after a single dose of FEIBA3
    - FEIBA has a 6 -12 hour dosing interval6
    - Factor II has demonstrated a prolonged half-life of about 72 hours3

Sustained activity

  • FEIBA contains factor II that has demonstrated a half-life of about 72 hours2
  • Thrombin generation with a single dose of FEIBA returns to baseline value after 8-12 hours2

FEIBA provides a long dosing interval (6-12 hours) that can give inhibitor patients more time to enjoy full and active lives. A long dosing interval7 can also be helpful for prophylactic use.


  1. 1. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
  2. 2. Turecek PL, Váradi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33:16-22.
  3. 3. Váradi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003;1:2374-2380.
  4. 4. Gill JC, Schwarz HP, Wentz MA, Montgomery RR. Platelet prothrombinase activity may predict successful activated prothrombin complex concentrate (FEIBA) treatment. Blood. 1990;76(suppl 1):399a.
  5. 5. Astermark J, Donfi eld SM, DiMichele DM, et al; for the FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546-551.
  6. 6. FEIBA Summary of Product Characteristics 2010.
  7. 7. Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007;13:256-263.
  8. 8. US National Hemophilia Foundation. MASAC Recommendation 167 Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=579. Accessed July 2011
  9. 9. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15:3-10.

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more


Learn how FEIBA prophylaxis may help protect your patients against bleeds. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more